2019. Completion of engineering
The company carries out the second stage of construction (engineering) and completes the rebranding project.
2018. The New Plant
Samson-Med completes the first stage of construction of a new plant and starts a rebranding project.
2017. The 80th Anniversary
The company celebrates its 80th anniversary.
The project of new facility construction is actively implemented.
Samson-Med co-operates with leading research institutes to develop and study new products.
2016. Strategic Importance
Samson-Med becomes a resident of St. Petersburg Import Substitution and Localisation Centre.
St. Petersburg Government recognises the strategic importance of the construction project in the Decree.
2010. Pharmaceutical Cluster
Samson-Med becomes a participant of St. Petersburg pharmaceutical cluster
2010. The Historic Agreement
The agreement about the construction of new production facility of Samson-Med signed by the Government of St. Petersburg.
2009. The decision to expand
The company decided to build a new production facility
1997. Samprost® production started
Samson-Med begins to produce Samprost®
1990. Two new products launch
The company completed development, registration and started to produce Mafusol and Polyoxifumarinum blood-substitution liquids.
1982. Thymalin® product launch
The company starts to produce Thymalin®
1978. Cytochrome C launch
Completion of the development and start of production of the injection form of Cytochrome C
1972. Plasma substitutes launch
The company begins production of plasma-substituting medicines (Disole, Trisole, Acesole), registration and start of production of Trypsin crystallisatum
1966-1969. Three new products launched
Company starts production of gelatinolum, Desoxyribonuclease and Pilocarpinum.
1963. Chymopsin and Chymotrypsin production
Company starts production of Chymopsin and crystallised Chymotrypsin.
1941-1945. During the War.
Company starts production of penicillin and insulin.
1937. Company Foundation
SamsonMed founded in 1937.